NHL Progression Risk Cut with Copanlisib–Rituximab Combo Available to Purchase

According to results from the phase III CHRONOS-3 trial, patients with relapsed indolent non–Hodgkin lymphoma may benefit significantly from the addition of copanlisib, a pan-PI3K inhibitor, to standard rituximab. The combination was safe and nearly halved the risk of disease progression or death, compared with placebo and rituximab.